ArticlePloS one2017
Maternal treatment with short-chain fatty acids modulates the intestinal microbiota and immunity and ameliorates type 1 diabetes in the offspring.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Pooled it
- Diet, gut microbiome, and type 1 diabetes: from risk to translational opportunity.Gut microbes · 2026Review
- Maternal diet shapes infant microbiota and defensive capacity against infections in early life via differential human milk composition.EBioMedicine · 2025Observational
- Maternal provisions in type 1 diabetes: Evidence for both protective & pathogenic potential.Frontiers in immunology · 2023Review
- The Urinary Microbiome; Axis Crosstalk and Short-Chain Fatty Acid.Diagnostics (Basel, Switzerland) · 2022Review
- Maternal obesity and resistance to breast cancer treatments among offspring: Link to gut dysbiosis.Cancer reports (Hoboken, N.J.) · 2022Review
- Microbial regulation of offspring diseases mediated by maternal-associated microbial metabolites.Frontiers in microbiology · 2022Review
- Article
- Microbiota Signals during the Neonatal Period Forge Life-Long Immune Responses.International journal of molecular sciences · 2021Review
- FFAR from the Gut Microbiome Crowd: SCFA Receptors in T1D Pathology.Metabolites · 2021Review
- Acetate, a Short-Chain Fatty Acid, Acutely Lowers Heart Rate and Cardiac Contractility Along with Blood Pressure.The Journal of pharmacology and experimental therapeutics · 2021Article
- Visceral Adipose Tissue: A New Target Organ in Virus-Induced Type 1 Diabetes.Frontiers in immunology · 2021Review
- Evidence for maternal diet-mediated effects on the offspring microbiome and immunity: implications for public health initiatives.Pediatric research · 2021Review
- Modulation of Intestinal ILC3 for the Treatment of Type 1 Diabetes.Frontiers in immunology · 2021Review
- Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes.Journal of virology · 2020Article
- Formate metabolism in health and disease.Molecular metabolism · 2020Review
- Impact of maternal dietary gut microbial metabolites on an offspring's systemic immune response in mouse models.Bioscience of microbiota, food and health · 2020Review
- Gastrointestinal Microbiota and Type 1 Diabetes Mellitus: The State of Art.Journal of clinical medicine · 2019Review
- Complex dietary polysaccharide modulates gut immune function and microbiota, and promotes protection from autoimmune diabetes.Immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We recently hypothesized that the intestinal microbiota and the innate immune system play key roles in the mechanism of Kilham Rat Virus-induced type 1 diabetes in the LEW1.WR1 rat. We used this animal model to test the hypothesis that maternal therapy with short-chain fatty acids can modulate the intestinal microbiota and reverse virus-induced proinflammatory responses and type 1 diabetes in rat offspring. We observed that administration of short-chain fatty acids to rat breeders via drinking water prior to pregnancy and further treatment of the offspring with short-chain fatty acids after weaning led to disease amelioration. In contrast, rats that were administered short-chain fatty acids beginning at weaning were not protected from type 1 diabetes. Short-chain fatty acid therapy exerted a profound effect on the intestinal microbiome in the offspring reflected by a reduction and an increase in the abundances of Firmicutes and Bacteroidetes taxa, respectively, on day 5 post-infection, and reversed virus-induced alterations in certain bacterial taxa. Principal component analysis and permutation multivariate analysis of variance tests further revealed that short-chain fatty acids induce a distinct intestinal microbiota compared with uninfected animals or rats that receive the virus only. Short-chain fatty acids downregulated Kilham Rat Virus-induced proinflammatory responses in the intestine. Finally, short-chain fatty acids altered the B and T cell compartments in Peyer's patches. These data demonstrate that short-chain fatty acids can reshape the intestinal microbiota and prevent virus-induced islet autoimmunity and may therefore represent a useful therapeutic strategy for disease prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.